Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SCD | O00767 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10008023 | 0.93 | KMT2A (0.63) | KMT2AALDH1A1SCDNPC1RAB9A | |
| SCHEMBL10299111 | 0.89 | ALDH1A1 (0.56) | KMT2AALDH1A1SCDNPC1RAB9A | |
| SCHEMBL10299454 | 0.89 | KMT2A (0.53) | KMT2AALDH1A1SCDNPC1RAB9A | |
| SCHEMBL10299101 | 0.88 | KMT2A (0.60) | KMT2AALDH1A1SCDNPC1RAB9A | |
| SCHEMBL10299098 | 0.88 | KMT2A (0.60) | KMT2AALDH1A1SCDNPC1RAB9A | |
| SCHEMBL10008539 | 0.87 | ALDH1A1 (0.62) | KMT2AALDH1A1SCDNPC1KDM4E | |
| SCHEMBL10299106 | 0.87 | NPC1 (0.44) | KMT2AALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL10299094 | 0.86 | KMT2A (0.58) | KMT2AALDH1A1SCDNPC1RAB9A | |
| SCHEMBL10009445 | 0.86 | ABL1 (0.57) | KMT2AALDH1A1SCDNPC1RAB9A | |
| SCHEMBL10009039 | 0.84 | KMT2A (0.51) | KMT2AALDH1A1SCDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | TUBB1, TUBA1C, TUBB | KMT2A 1778/4885ALDH1A1 2950/4885SCD 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.